Research programme: cancer therapeutics - Alaunos Therapeutics
Latest Information Update: 15 Dec 2023
At a glance
- Originator Alaunos Therapeutics
- Class Antineoplastics; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 24 Nov 2023 Early research in Cancer in USA (Parenteral) (Alaunos Therapeutics pipeline, November 2023)